About Lymphoma | Advocacy | Art | CAM | Clinical trials | Doctors - Experts - Centers | Guidelines at Diagnosis | News
Risk Factors | Side Effects | Statistics | Support | Symptoms | Tests | Treatments | Types of Lymphoma

Search Site         Guidelines at Diagnosis | About Clinical Trials            How to Help!

Patients Against Lymphoma

 

Treatment Overview or Chemotherapy > Liposomal 

Last update: 12/09/2013

 Liposomal doxorubicin | Liposomal Vincristine | Resources & Research News

ASH Paper, 2013: Long Term Results Of a Phase 2 Study Of Vincristine Sulfate Liposome Injection (Marqibo) Substituted For Non-Liposomal Vincristine In CHOP With Or Without Rituximab For Patients With Untreated Aggressive Non-Hodgkin’s Lymphomas http://bit.ly/ILW9le

Treatment agents "can be encapsulated in long-circulating Stealth liposomes. Liposomes are microscopic vesicles composed of a phospholipid bilayer that are capable of encapsulating active drugs. The Stealth liposomes are formulated with surfacebound methoxypolyethylene glycol, a process often referred to as pegylation, to protect liposomes from detection by the mononuclear phagocyte system and to increase blood circulation time. It is hypothesized that liposomal drug molecules are able to penetrate the vasculature of tumours."

Source:  Liposomal Doxorubicin - cancercare - PDF 
New developments:

Liposomal antisense - Related articles 

Immunoliposomal anticancer drugs:
Improved outcome when B-cell lymphoma is treated with combinations of immunoliposomal 
anticancer drugs targeted to both the CD19 and CD20 epitopes (antigens). 
Clin Cancer Res. 2004 Apr 1;10(7):2530-7. PMID: 15073133 | Related Articles | Background


Recommended Resources:

Liposomes are microscopic spherical vesicles that form when phospholipids are hydrated.
Evaluation of Drug Targeting Strategies and Liposomal Trafficking - bentham.org
About liposomes - collabo.com 
Return to top

 


Liposomal doxorubicin (Doxil™, Caelyx®, Myocet®

Doxorubicin (anthracyclines) can effectively treat aggressive and transformed lymphoma.  However, the use of this chemotherapy agent is limited by its toxicity, particularly to the heart.  A liposome encapsulated form of the drug called Doxil appears to be safer, and early indications are encouraging in respect to responses (see below), but most experts believe that more clinical data and long-term assessment of side effects are needed before it can be used routinely as a frontline substitution for doxorubicin. [1]

Mechanism: "Pegylated-liposomal doxorubicin (Doxil™) is a unique form of liposomal doxorubicin in which the liposomes are coated with polyethylene glycol. The polyethylene glycol confers useful properties including a diminished uptake by the reticuloendothelial system, leading to a much longer half-life in blood (~50-60 hours), and a different toxicity profile than non-pegylated liposomes. " - cancer.med.umich.edu

NOTE: "Avoid hot showers or baths, steam baths or hot tubs 24 before and for 72 hours after treatment with liposomal doxorubicin. This may help decrease the occurrence of certain skin reactions." -  jasper-web.com 

Resources:
  1. Pegylated Liposomal Doxorubicin: Tolerability and Toxicity - Medscape (free login req.) 02_01_03 
  2. About  - cancerbacup.org.uk 
  3. Evaluation of Drug Targeting Strategies and Liposomal Trafficking - bentham.org
  4. Liposomal Doxorubicin - cancercare - PDF 
  5. Side effects - Cardiac - PAL |  
  6. Side effect relief - Do's and Don'ts - cancerlynx.com 
  7. Full prescribing information from the sponsor - Pdf 
Treatment-Related Abstracts:
  • Pegylated liposomal doxorubicin as single-agent treatment of low-grade non-Hodgkin's lymphoma: 
    a phase II multicenter study. Clin Lymphoma. 2003 Mar;3(4):235-40. PMID: 12672273 | Related articles
  • Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T-cell lymphoma. 
    Cancer. 2003 Sep 1;98(5):993-1001. PMID: 12942567
  • Pegylated liposomal doxorubicin in combination chemotherapy in the treatment of previously 
    untreated aggressive diffuse large-B-cell lymphoma. Med Oncol. 2002;19(1):55-8. PMID: 12025891 - PubMed
  • Treatment of relapsing or recalcitrant cutaneous T-cell lymphoma with pegylated liposomal doxorubicin. 
    J Am Acad Dermatol. 2000 Jan;42(1 Pt 1):40-6. PMID: 10607318 -  PubMed
  • Cyclophosphamide, pegylated liposomal doxorubicin (Caelyx"), vincristine and prednisone (CCOP) 
    in elderly patients with diffuse large B-cell lymphoma: results from a prospective phase II study. 
    Haematologica. 2002 Aug;87(8):822-7. PMID: 12161358 - PubMed
  • Targeted delivery and triggered release of liposomal doxorubicin enhances cytotoxicity against 
    human B lymphoma cells. Biochim Biophys Acta. 2001 Dec 1;1515(2):144-58. PMID: 11718670 - PubMed 
  • LIPOSOMAL DOXORUBICIN: A phase I/II trial of liposomal doxorubicin (TLC D-99, Myocet) with 
    cyclophosphamide, vincristine, and prednisone in newly diagnosed aggressive NHL
     Year: 2002 Abstract No: 1133
Return to top


Liposomal Vincristine (ONCO-TCS)

ONCO-TCS - The TCS means transmembrane carrier systems.  It's a drug delivery system that uses a lipid envelope to encapsulate intravenous chemotherapeutic drugs, allowing them to circulate in the bloodstream for several hours after injection and selectively accumulate at a disease site.  It's an investigational therapy being tested currently for aggressive NHL. Sponsor describes technology with animation here:  INEX
 
  • Marqibo Not Eligible For Accelerated Approval, Committee Says -  fdaadvisorycommittee.com  
    "Inex/Enzon’s liposomal vincristine injection Marqibo should not be eligible for accelerated approval since there are other therapies for relapsed non-Hodgkin’s lymphoma, FDA’s Oncologic Drugs Advisory Committee agreed Dec. 1."
  • Inex Pharmaceuticals initiates submission of New Drug Application for Onco TCS to the United States FDA - newswire.ca Oct_03
  • Phase I study of liposomal vincristine. J Clin Oncol. 1999 Feb;17(2):697-705. PMID: 10080616 - PubMed | Related abstracts
  • INEX achieves positive pivotal Phase II/III clinical trial results to seek FDA marketing approval for Onco TCS (liposomal vincristine) for relapsed aggressive non-Hodgkin's lymphoma (NHL). - Newswire Dec_03_02
  • Liposomal vincristine in relapsed non-Hodgkin's lymphomas: early results of an ongoing phase II trial.
    Ann Oncol. 2000 Jan;11(1):69-72. PMID: 10690390 - PubMed
  • Onco TCS: first-line treatment for the aggressive form of NHL Will it replace the current standard,  CHOP + Rituxan?
     - INEX 11_07_2
  • Preclinical pharmacology, toxicology and efficacy of sphingomyelin/cholesterol liposomal vincristine for therapeutic treatment of cancer - springer-ny.com
  • Encapsulation of vincristine in liposomes reduces its toxicity and improves its anti-tumor efficacy. -  liposomes.ubc.ca
  • LIPOSOMAL VINCRISTINE: A phase II study of liposomal vincristine in CHOP with rituximab for elderly patients with untreated aggressive B-cell non-Hodgkin's lymphoma (NHL). Year: 2002 Abstract No: 1132
Return to top
 
Disclaimer:  The information on Lymphomation.org is not intended to be a substitute for 
professional medical advice or to replace your relationship with a physician.
For all medical concerns,  you should always consult your doctor. 
Patients Against Lymphoma, Copyright © 2004,  All Rights Reserved.